P663: Efficacy of jak inhibitors in inflammatory bowel disease patients with extraintestinal manifestations– Retrospective studyECCO'24Year: 2024
Authors: Livne Margolin, M.(1)*;González Lama2, Y.(2);Koutroubakis, I.(3);Drygiannakis, I.(4);Shitrit, A.(5);Goldenberg , R.(5);Farkas, K.(6); Molnar , T.(6);Ivány, E.(7);Amiot, A.(8); Carbonnel, F.(9);Girod, P.(10);Doherty, G.(11);Mateescu, B.(12);Ben-Horin1, S.(13);Kopylov, U.(1);
(1)Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(2)Hospital Universitario Puerta de Hierro, Gastroenterology and Hepatology Dpt, Madrid, Spain;(3)hospital heraklion, Gastroenterology department, Crete, Greece;(4)Heraklion University Hospital, Department of gastroenterology, Crete, Greece;(5)Shaare Zedek Medical Center, department of gastroenterology, Jerusalem, Israel;(6)University of Szeged, Department of medicine, Szeged, Hungary;(7)Aranyklinika medical center, department of gastroenterology, Szeged, Hungary;(8)University Paris Est Creteil, Department of gastroenterology, Paris, France;(9)University of Paris Est Creteil, Department of gastroenterology, Paris, France;(10)St. Vincent’s University Hospital, Department of gastroenterology, Dublin, Ireland;(11)St. Vincent@E@s University Hospital, Department of Gastroenterology- Centre for Colorectal Disease, Dublin, Ireland;(12)Colentina Clinical Hospital, Gastroenterology Department, Bucharest, Romania;(13)Sheba medical center, Department of gastroenterolgy, Ramat Gan, Israel;
P664: Anti-TNF exposure is associated with an increased risk of urgent and one-year colectomy in Acute Severe Ulcerative ColitisECCO'24Year: 2024
Authors: Bourgonje, A.R.(1)*;Posner, H.(1);Mehandru, S.(1);Colombel, J.F.(1);Kayal, M.(1);
(1)Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;
P665: Statins use and the risk of colorectal cancer in patients with inflammatory bowel disease: A Systematic review and meta-analysisECCO'24Year: 2024
Authors: Jung, B.W.(1);Lee, W.M.(2)*;Choi , S.(3);Lee, H.S.(4);ParkAssistant professor, J.J.(3);
(1)Hanyang University Guri Hospital- Hanyang University College of Medicine, Internal Medicine, Guri, Korea- Republic Of;(2)SoonChunHyang University Hospital, Internal medicine, Bucheon, Korea- Republic Of;(3)Severance Hospital- Yonsei University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(4)Yonsei University College of Medicine, Biostatics Collaboration Unit, Seoul, Korea- Republic Of;
P666: Accuracy of information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO guidelinesECCO'24Year: 2024
Authors: Farrugia, Y.(1)*;Sciberras, M.(1);Gordon, H.(2);Furfaro, F.(3);Allocca, M.(3);Torres, J.(4);Arebi, N.(5);Fiorino , G.(3);Iacucci , M.(6);Verstockt , B.(7);Magro, F.(8);Katsanos , K.(9);Fenech, V.A.(1);Chetcuti Zammit , S.(1);Ellul, P.(1);
(1)Mater Dei Hospital- Malta, Department of Medicine- Division of Gastroenterology, Msida, Malta;(2)Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(3)IRCCS OSPEDALE San Raffaele, Department of Gastroenterology and Endoscopy, Milan, Italy;(4)Hospital Beatriz Ângelo, Division of Gastroenterology, Loures, Portugal;(5)St Mark@E@s National Bowel Hospital, Department of Inflammatory Bowel Disease, London, United Kingdom;(6)School of Medicine University College Cork, Gastroenterology, Cork, Ireland;(7)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(8)CINTESIS@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal;(9)University of Ioannina School of Health Sciences, Division of Gastroenterology- Department of Internal Medicine, Ioannina, Greece;
P667: Benefit of 5-ASA continuation on UC disease outcomes following initiation of a biologicECCO'24Year: 2024
Authors: Tomasic, V.(1)*;Biscanin, A.(2,3);Cacic, P.(1);Babic, F.(1);Burcul, I.(4);Dorosulic, Z.(1);Kralj, D.(1);Ogresta Kordej, D.(1);Hrabar, D.(1,3);
(1)University Hospital Centre Sestre milosrdnice, Department of gastroenterology and hepatology, Zagreb, Croatia;(2)University Hospital Center Sestre milosrdnice, Department of gastroenterology and hepatology, Zagreb, Croatia;(3)University of Zagreb- School of Medicine, Internal medicine, Zagreb, Croatia;(4)General hospital Karlovac, Division of Internal medicine, Karlovac, Croatia;
P668: Dashboard-guided anti-TNF induction as an effective proactive strategy in Inflammatory Bowel Disease@E@s treatment.ECCO'24Year: 2024
Authors: Céspedes Martínez, E.(1)*;Robles-Alonso, V.(1);Herrera-De Guise, C.(1);Mayorga, L.(1);Serra, X.(1);Pérez , Z.(1);Oller, E.(1);Larrosa, M.(2);García-García, S.(2);Casellas, F.(1);Borruel, N.(1);
(1)Hospital Universitario Vall d@E@Hebron, Unitat d@E@Atenció Crohn-Colitis UACC- Gastroenterology Department, Barcelona, Spain;(2)Hospital Universitario Vall d@E@Hebron, Pharmacokinetic and pharmacogenetic Unit- Pharmacy Department, Barcelona, Spain;
P669: Efficacy of Ustekinumab-based integrated medicine therapy in patients with symptomatic stricturing Crohn@E@s disease: a multicentre, prospective, observational cohort studyECCO'24Year: 2024
Authors: Liu, J.(1);Hu, W.(1);Li, S.(2);Xu, D.(1);Wu, Q.(1);Chen, Y.(3)*;
(1)The Second Affiliated Hospital of Zhejiang University School of Medicine, Gastroenterology Department, Hangzhou, China;(2)The Second Affiliated Hospital of Zhejiang University School of Medicine, Nursing Department, Hangzhou, China;(3)The Second Affiliated Hospital- Zhejiang University School of Medicine, Inflammatory Bowel Disease Center- Department of Gastroenterology, Hangzhou, China;
P672: Occurrence of malignancy among infliximab biosimilar and bio-originator initiators in Canada: a comparative population-based analysisECCO'24Year: 2024
Authors: Birck, M.G.(1);Lukusa, L.(1);Singh, H.(2);Narula, N.(3);Targownik, L.E.(4);Leung, Y.(5);Afif, W.(6)*;Bernatsky, S.(1);
(1)Research Institute of the McGill University Health Centre, Centre for Outcomes Research and Evaluation, Montreal, Canada;(2)University of Manitoba, Max Rady College of Medicine, Winnipeg, Canada;(3)Hamilton Health Sciences, Division of Gastroenterology and Hepatology, Hamilton, Canada;(4)Mount Sinai Hospital, Division of Gastroenterology and Hepatology, Toronto, Canada;(5)University of British Columbia, Department of Medicine and Division of Gastroenterology, Vancouver, Canada;(6)McGill University, Division of Gastroenterology and Hepatology, Montreal, Canada;
P673: Accelerated intravenous ustekinumab dosing as rescue therapy in Moderate- Severe Ulcerative ColitisECCO'24Year: 2024
Authors: Muñoz Villafranca, M.D.C.(1)*;Arreba, P.(1);Buendia, L.(1);Higuera, R.O.(1);López, M.L.(1);Prado, N.F.(1);Irusta, L.(1);Jiménez, M.A.(1);Aldama, M.(1);Santacruz, M.(1);Perez, A.(1);Rodriguez, P.(1);Bilbao, A.(2);Ortiz de Zárate, J.(1);
(1)Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain;(2)Hospital Universitario de Basurto, Research Unit, Bilbao, Spain;
P674: Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatmentECCO'24Year: 2024
Authors: Bacsur, P.(1)*;Resál, T.(1);Farkas, B.(1);Sarlós, P.(2);Iliás, Á.(3);Kata, D.(4);Bálint, A.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Molnár, T.(1);Farkas, K.(1);
(1)Albert Szent-Györgyi Medical School- University of Szeged, Department of Medicine, Szeged, Hungary;(2)University of Pécs, Division of Gastroenterology- First Department of Medicine, Pécs, Hungary;(3)Semmelweis University, First Department of Medicine, Budapest, Hungary;(4)Albert Szent-Györgyi Medical School- University of Szeged, Institute of Laboratory Medicine, Szeged, Hungary;
P675: Comparative efficacy of Infliximab, Adalimumab, and Ustekinumab in patients with biologics naive Crohn@E@s disease：a retrospective observational single-center studyECCO'24Year: 2024
Authors: Sakurai, K.(1)*;Takahashi, S.(1);Fujihata, K.(1);Watanabe, R.(1);Nishimura, Y.(1);Yamada, R.(1);Sawada, K.(1);Sano, I.(1);Oda, H.(1);Miyagishima, T.(1);
(1)Kushiro Rosai Hospital, Department of Gastroenterology, Kushiro City- Hokkaido, Japan;
P676: Unveiling the impact on in utero exposure to biologic treatments for inflammatory bowel disease (IBD) on children@E@s psychomotor development: Insights from the DUMBO registry of GETECCU.ECCO'24Year: 2024
Authors: Palomino Pérez, L.M.(1)*;Velasco Rodríguez-Belvís, M.(1);Brenes Ruiz, Y.(2);Leo-Carnerero, E.(3);Calviño Suarez, C.(4);Rivero, M.(5);Calvo, M.(6);Arroyo, M.T.(7);Fernández-Clotet, A.(8);Pérez-Martínez, I.(9);Masedo González, Á.(10);Hernández, V.(11);Ruiz-Cerulla, A.(12);López Serrano, P.(13);Vega, P.(14);Rodríguez-Lago, I.(15);Vicente Lidón, R.(16);De Jorge, M.Á.(17);Guerra, I.(18);Arias García, L.(19);Molina Arriero, G.(20);Hervías Cruz, D.(21);Busquets, D.(22);Gutiérrez Casbas, A.(23);Van Domselaar, M.(24);Valldosera Gomis, G.(25);Vázquez Morón, J.M.(26);Piqueras Cano, M.(27);Lucendo, A.J.(28);Martín Arranz, M.D.(29);Ramírez de la Piscina, P.(30);Martínez Tirado, M.D.P.(31);Robles Alonso, V.(32);Marín Pedrosa, S.(33);Camargo Camero, R.(34);Armesto Gonzalez, E.(35);García-Salido, A.(36);Muñoz Codoceo, R.(1);Gisbert*, J.P.(2);Chaparro*, M.(2);
(1)Hospital Infantil Universitario Niño Jesús, Gastroenterology and Nutrition Unit, Madrid, Spain;(2)Hospital Universitario de La Princesa. Instituto de Investigación Sanitaria Princesa IIS-IP- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Unit, Madrid, Spain;(3)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(4)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(5)Hospital Universitario Marqués de Valdecilla e IDIVAL, Gastroenterology Unit, Santander, Spain;(6)Hospital Universitario Puerta de Hierro, Gastroenterology Unit, Majadahonda, Spain;(7)Hospital Clínico Universitario Lozano Blesa. IIS Aragón y CIBERehd, Gastroenterology Unit, Zaragoza, Spain;(8)Hospital Clinic de Barcelona. Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBERehd. Institut d@E@Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Gastroenterology Unit, Barcelona, Spain;(9)Hospital Universitario Central de Asturias. Diet- Microbiota and Health Group. Instituto de Investigación Sanitaria del Principado de Asturias ISPA., Gastroenterology Unit, Oviedo, Spain;(10)Hospital Universitario 12 de octubre, Gastroenterology Unit, Madrid, Spain;(11)Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación de Patología Digestiva. Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS UVIGO, Gastroenterology Unit, Vigo, Spain;(12)Hospital Universitario de Bellvitge- L@E@Hospitalet de Llobregat, Gastroenterology Unit, Barcelona, Spain;(13)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain;(14)Complexo Hospitalario Universitario de Ourense, Gastroenterology Unit, Ourense, Spain;(15)Hospital Universitario de Galdakao. Biobizkaia Health Research Institute, Gastroenterology Unit, Bizkaia, Spain;(16)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(17)Hospital Universitario de Cabueñes, Gastroenterology Unit, Asturias, Spain;(18)Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain;(19)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(20)Complejo Hospitalario Universitario de Ferrol, Gastroenterology Unit, A Coruña, Spain;(21)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(22)Hospital Trueta de Girona, Gastroenterology Unit, Girona, Spain;(23)Hospital General Universitario Dr. Balmis Alicante. ISABIAL- CIBERehd, Gastroenterology Unit, Alicante, Spain;(24)Hospital Universitario de Torrejón- Universidad Francisco de Vitoria, Gastroenterology Unit, Madrid, Spain;(25)Hospital Universitario Joan XXIII, Gastroenterology Unit, Tarragona, Spain;(26)Hospital Universitario Juan Ramón Jimenez, Gastroenterology Unit, Huelva, Spain;(27)Consorci Sanitari de Terrassa CST, Gastroenterology Unit, Barcelona, Spain;(28)Hospital General de Tomelloso. Instituto de Investigación Sanitaria La Princesa- Spain- Instituto de Investigación Sanitaria de Castilla-La Mancha IDISCAM- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Ciudad Real, Spain;(29)Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain;(30)Hospital Universitario de Álava, Gastroenterology Unit, Álava, Spain;(31)Hospital Clínico Universitario San Cecilio, Gastroenterology Unit, Granada, Spain;(32)Hospital Vall d´Hebrón, Gastroenterology Unit, Barcelona, Spain;(33)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(34)Hospital Universitario Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain;(35)Hospital Universitario San Agustín, Gastroenterology Unit, Avilés, Spain;(36)Hospital Infantil Universitario Niño Jesús, Intensive Care Unit, Madrid, Spain;On behalf of the DUMBO project of GETECCU. *Authors share senior authorship
P677: The Oxford Anti-TNF Study of Immunogenicity and Sustained Response (OASIS-IBD): Analysis of 40,000 Patient Years of Anti-TNF UseECCO'24Year: 2024
Authors: Al-Hillawi, L.(1,2)*;Liao, H.(3);Powell Doherty, R.(2);Bedke, N.(4);Azzu, H.(5);Cripps, S.(5);Prabhu, A.(1);White, L.(1);Ambrose, T.(1);Cheung, V.(1);Palmer, R.(1);Walsh, A.(1,2);Travis, S.(6);Ternette, N.(2,7);Brain, O.(1,2);Satsangi, J.(1,2);
(1)Oxford University Hospitals NHS Foundation Trust, Department of Gastroenterology- John Radcliffe Hospital, Oxford, United Kingdom;(2)University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom;(3)University of Oxford, Jenner Institute, Oxford, United Kingdom;(4)University of Oxford, Nuffield Department of Medicine- Center for Immuno-oncology, Oxford, United Kingdom;(5)Oxford University Hospitals NHS Foundation Trust, Pharmacy Department- John Radcliffe Hospital, Oxford, United Kingdom;(6)Kennedy Institute of Rheumatology, Biomedical Research Centre, Oxford, United Kingdom;(7)University of Oxford, Nuffield Department of Medicine - Centre for Cellular and Molecular Physiology, Oxford, United Kingdom;The Oxford Anti-TNF Study of Immunogenicity and Sustained Response (OASIS-IBD)
P678: Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTEECCO'24Year: 2024
Authors: FeaganSenior Scientific Officer, B.G.(1,2)*;Matsuoka, K.(3);Rogler, G.(4);Laharie, D.(5);Vermeire, S.(6);Danese, S.(7,8);Loftus- Jr, E.V.(9);Beales, I.(10,11);Schreiber, S.(12);Kim, H.J.(13);Faes, M.(14);Masior, T.(15);Rudolph, C.(16);Peyrin-Biroulet, L.(17,18,19,20,21,22);
(1)Alimentiv Inc., Senior Scientific Director, London ON, Canada;(2)Western University, Division of Gastroenterology- London Health Sciences Centre, London ON, Canada;(3)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Chiba, Japan;(4)University Hospital Zurich- University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;(5)Hospital Center University de Bordeaux- Magellan Medico-Surgical Center- Haut-Lévêque Hospital- University of Bordeaux- Inserm, Department of Gastroenterology, Bordeaux, France;(6)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(7)IRCCS Hospital San Raffaele, Department of Gastroenterology and Digestive Endoscopy, Milan, Italy;(8)Vita-Salute San Raffaele University, Department of Gastroenterology, Milan, Italy;(9)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester MN, United States;(10)Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Gastroenterology, Norwich, United Kingdom;(11)University of East Anglia, Department of Gastroenterology, Norwich, United Kingdom;(12)Kiel University- University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(13)College of Medicine- Kyung Hee University, Department of Internal Medicine, Seoul, Korea- Republic Of;(14)Galapagos NV, Biostatistics, Mechelen, Belgium;(15)Galapagos GmbH, Clinical Development, Basel, Switzerland;(16)Galapagos B.V., Medical Affairs, Leiden, The Netherlands;(17)Nancy University Hospital, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(18)McGill University Health Centre, Division of Gastroenterology and Hepatology, Montreal QC, Canada;(19)Paris IBD Center, Ambroise Paré – Hartmann Private Hospital Group, Neuilly-sur-Seine, France;(20)Nancy University Hospital, FHU Curing and Preventing IMID CURE, Vandœuvre-lès-Nancy, France;(21)Nancy University Hospital, INFINY Institute, Vandœuvre-lès-Nancy, France;(22)University of Lorraine, Inserm- NGERE, Nancy, France;
P679: Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial.ECCO'24Year: 2024
Authors: Vuitton, L.(1)*;Poullenot , F.(2);Bouhnik, Y.(3);Wils, P.(4);Buisson, A.(5);Viennot, S.(6);Bouguen , G.(7);Hébuterne, X.(8);Gilletta, C.(9);Nancey, S.(10);Bourreille, A.(11);Amil, M.(12);Altwegg, R.(13);Goutorbe, F.(14);Caillo, L.(15);Plastaras, L.(16);Brixi, H.(17);Simon, M.(18);Serrero, M.(19);Fumery, M.(20);Rahier, J.F.(21);Vicaut, E.(22);Peyrin-Biroulet, L.(23);
(1)CHU Besançon, Department of Gastroenterology, Besançon, France;(2)CHU Bordeaux, Department of Gastroenterology, Bordeaux, France;(3)APHP Hopital Beaujon and Institut des MICI, Department of Gastroenterology, Neuilly and Créteil, France;(4)CHU Lille, Department of Hepatogastroenterology, Lille, France;(5)CHU Clermont-Ferrand, Department of Gastroenterology, Clermont-Ferrand, France;(6)CHU Caen, Department of Gastroenterology, Caen and Paris, France;(7)CHU Rennes, Department of Gastroenterology, Rennes, France;(8)CHU Nice, Department of Gastroenterology, Nice, France;(9)CHU Toulouse, Department of Gastroenterology, Toulouse, France;(10)CHU Lyon Sud, Department of Gastroenterology, Lyon, France;(11)CHU Nantes, Department of Gastroenterology, Nantes, France;(12)CH La Roche Sur Yon, Department of Gastroenterology, La Roche Sur Yon, France;(13)CHU Montpellier, Department of Gastroenterology, Montpellier, France;(14)CH Bayonne, Department of Gastroenterology, Bayonne, France;(15)CHU Nimes, Department of Gastroenterology, Nimes, France;(16)CH Colmar, Department of Gastroenterology, Colmar, France;(17)CHU Reims, Department of Gastroenterology, Reims, France;(18)Institut Montsouris, Department of Gastroenterology, Paris, France;(19)APHM Hopital Nord Marseille, Department of Gastroenterology, Marseille, France;(20)CHU Amiens, Department of Gastroenterology, Amiens, France;(21)CHU Namur, Department of Gastroenterology, Namur, Belgium;(22)APHP, Methodology, Paris, France;(23)CHU Nancy, Department of Gastroenterology, Nancy, France;
P680: Comparative risk of serious infection with vedolizumab vs anti-TNF in Inflammatory Bowel Disease: Results from nationwide Swedish registersECCO'24Year: 2024
Authors: Karlqvist, S.(1)*;Sachs, M.(2,3);Eriksson, C.(1,4);Cao, Y.(5,6);Montgomery, S.(4,5,7);Ludvigsson, J.F.(3,8,9);Olén, O.(4,10);Halfvarson, J.(1);
(1)Örebro University, Department of Gastroenterology, Örebro, Sweden;(2)University of Copenhagen, Department of Public Health, Copenhagen, Denmark;(3)Karolinska Institute, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden;(4)Karolinska Institute, Department of Medicine Solna, Stockholm, Sweden;(5)Örebro University, Clinical Epidemiology and Biostatistics, Örebro, Sweden;(6)Institute of Environmental Medicine- Karolinska Institute, Unit of Integrative Epidemiology, Stockholm, Sweden;(7)University College London, Department of Epidemiology and Public Health, London, United Kingdom;(8)Columbia University College of Physicians and Surgeons, Department of Medicine, New York, United States;(9)Örebro University Hospital, Department of Paediatrics, Örebro, Sweden;(10)Stockholm South General Hospital, Sachs@E@ Children and Youth Hospital, Stockholm, Sweden;The SWIBREG Study Group
P681: Preliminary data from the Biologic and Partial Enteral Nutrition in Crohn’s Disease Study (BIOPIC)ECCO'24Year: 2024
Authors: White, B.(1)*;Jatkowska, A.(1);Campbell, I.(2);Brownson, E.(2);Short, B.(1);Clowe, J.(1);Seenan, J.P.(2);Gaya, D.(3);Din, S.(4);Ho, G.T.(4);Robertson, E.(5);Mowat, C.(6);Milling, S.(7);Macdonald, J.(8);Gerasimidis, K.(1);
(1)University of Glasgow, Department of Human Nutrition, Glasgow, United Kingdom;(2)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;(3)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(4)Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom;(5)University Hospital Hairmyres, Department of Gastroenterology, East Kilbride, United Kingdom;(6)Ninewells Hospital, Department of Gastroenterology, Dundee, United Kingdom;(7)University of Glasgow, School of Infection & Immunity, Glasgow, United Kingdom;(8)Queen Elizabeth Univeristy Hospital, Department of Gastroenterology, Glasgow, United Kingdom;
P682: A Retrospective Comparison of Different Treatment Modalities in Patients with Chronic PouchitisECCO'24Year: 2024
Authors: Uchitel, Y.(1)*;Cohen, N.A.(1);Hirsch, A.(1);Tulchinsky, H.(2);Zemel, M.(2);Maharshak, N.(1);
(1)Tel Aviv Medical Center, Gastroenterology, Tel Aviv, Israel;(2)Tel Aviv Medical Center, General Surgery, Tel Aviv, Israel;
P683: Economic impact of achieving mucosal healing on UC-related hospitalisations and work productivity in patients with moderately to severely active UC: A post-hoc analysis of risankizumab Phase 2b/3 trialsECCO'24Year: 2024
Authors: Peyrin-Biroulet, L.(1)*;Ungaro, R.(2);Rubin, D.T.(3);Bokemeyer, B.(4);Ricart, E.(5);Levine, P.(6);Lai, J.H.(7);Sharma, D.(6);Vladea, R.(6);Sanchez Gonzalez, Y.(6);Patel, K.(8);
(1)Department of Gastroenterology- University of Lorraine- CHRU-Nancy and University of Lorraine- Inserm- NGERE, none, Nancy, France;(2)Icahn School of Medicine at Mount Sinai, Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;(3)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(4)Gastroenterology Practice Minden, none, Minden, Germany;(5)Inflammatory Bowel Disease Unit- Department of Gastroenterology- Hospital Clínic- IDIBAPS and Biomedical Research Networking Center in Hepatic and Digestive Diseases CIBERehd, none, Barcelona, Spain;(6)AbbVie Inc., none, North Chicago, United States;(7)AbbVie Inc. and Health Outcomes Division- College of Pharmacy- University of Texas at Austin, none, Austin, United States;(8)St George’s University Hospital, NHS Foundation Trust, London, United Kingdom;
P684: Using a pharmacokinetic simulation model to determine the optimal infliximab intensification strategy to address loss of response in inflammatory bowel diseaseECCO'24Year: 2024
Authors: Srinivasan, A.(1,2,3)*;Upton, R.(4);
(1)Austin Health, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Gastroenterology, Melbourne, Australia;(3)Eastern Health, Department of Gastroenterology, Melbourne, Australia;(4)University of South Australia, Clinical & Health Sciences-, Adelaide, Australia;